TPST
Tempest Therapeutics, Inc. [TPST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TPST Stock Summary
Top TPST Correlated Resources
TPST
Top 10 Correlated ETFs
TPST
Top 10 Correlated Stocks
TPST
In the News
TPST Financial details
Company Rating
-
Market Cap
79.67M
Income
-29.89M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
17
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.97
Forward P/E
-
PEG
0.51
P/S
-
P/B
-53.52
P/C
-
P/FCF
-3.08
Quick Ratio
1.5
Current Ratio
1.66
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.95
EPS next Y
-
EPS next Q
-
EPS this Y
-39.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-27.08%
-
-
-
-
SMA20
-20%
SMA50
-33.33%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-135%
ROE
-394%
ROC
-1.85%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.17-9.77
52W High
-
52W Low
-
RSI
41
Rel Volume
0.06
Avg Volume
1.02M
Volume
62.89K
Perf Week
-6.73%
Perf Month
-33.86%
Perf Quarter
-45.62%
Perf Half Y
-50.56%
-
-
-
-
Beta
-2.827
-
-
Volatility
0.33%, 1.54%
Prev Close
-3.68%
Price
7.07
Change
-10.39%
Company Profile
- Volume Average 1.02M
- Market Capitalization 79.67M
- Employee 17
- CEO Mr. Stephen R. Brady J.D., LLM
- Headquarters South San Francisco,CA,US
- IPO Date 2012-11-12
-
Website
https://www.tempesttx.com 
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
